scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1027601311 |
P356 | DOI | 10.1038/SJ.BJC.6601910 |
P932 | PMC publication ID | 2364740 |
P698 | PubMed publication ID | 15173860 |
P5875 | ResearchGate publication ID | 8532693 |
P50 | author | Giuseppe Giaccone | Q37829946 |
P2093 | author name string | W R Gerritsen | |
F A E Kruyt | |||
D C J Mastenbroek | |||
M A I Abou El Hassan | |||
P2860 | cites work | The receptor for the cytotoxic ligand TRAIL | Q24310481 |
Identification and characterization of a new member of the TNF family that induces apoptosis | Q24318423 | ||
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family | Q24320301 | ||
Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL | Q24554360 | ||
An antagonist decoy receptor and a death domain-containing receptor for TRAIL | Q28245153 | ||
Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480. | Q31145220 | ||
Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells | Q32107279 | ||
Safety and antitumor activity of recombinant soluble Apo2 ligand | Q33855449 | ||
Potential and caveats of TRAIL in cancer therapy | Q34625563 | ||
Apoptosis: target of cancer therapy. | Q34735786 | ||
Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy | Q35002472 | ||
TRAIL-induced signalling and apoptosis | Q35082292 | ||
Impact of proapoptotic proteins Bax and Bak in tumor progression and response to treatment | Q35204983 | ||
The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro | Q36670985 | ||
Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. | Q40751646 | ||
Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells | Q40761393 | ||
Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. | Q40832569 | ||
Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis | Q40860890 | ||
Recombinant adenovirus vectors with knobless fibers for targeted gene transfer | Q40906930 | ||
Defining characteristics of Types I and II apoptotic cells in response to TRAIL. | Q41687820 | ||
CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release | Q43682296 | ||
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications | Q43684721 | ||
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. | Q43696432 | ||
Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice | Q44183123 | ||
The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells. | Q44393123 | ||
Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft | Q45855281 | ||
Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety | Q46661382 | ||
Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. | Q53950070 | ||
Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). | Q54033342 | ||
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. | Q55473556 | ||
Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect | Q63865750 | ||
Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect | Q64377565 | ||
Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes | Q64378684 | ||
Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene | Q64379934 | ||
Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells | Q73405489 | ||
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions | Q73704158 | ||
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand | Q73766150 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Adenoviridae | Q193447 |
overexpression | Q61643320 | ||
P304 | page(s) | 171-177 | |
P577 | publication date | 2004-07-01 | |
P1433 | published in | British Journal of Cancer | Q326309 |
P1476 | title | Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. | |
P478 | volume | 91 |
Q33907576 | A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. |
Q38330182 | Adenovirus E1B 19-kilodalton protein modulates innate immunity through apoptotic mimicry. |
Q55451018 | Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps. |
Q43184280 | MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma |
Q38120523 | Role of the Crosstalk between Autophagy and Apoptosis in Cancer |
Q36611974 | Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterations |
Q36654996 | Structure-activity relationship studies of naphthol AS-E and its derivatives as anticancer agents by inhibiting CREB-mediated gene transcription |
Q34076762 | Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3'-UTR microRNA |
Q34042769 | The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene |
Q42946052 | The Human Lung Cancer Drug Resistance-Related Gene BC006151 Regulates Chemosensitivity in H446/CDDP Cells |
Search more.